Aytu BioPharma reports Q1 FY2026 revenue $13.9M, net income $2.0M; EXXUA launch on track

AYTU BIOPHARMA, INC

2026-Q1 EPS reported -$0.08 vs consensus -$0.52 ▲ beat (+84.6%)

Net revenue $13.9M vs $16.6M year ago; ex-one-time rebate of $3.3M, revenue up 5% YoY.
ADHD portfolio net revenue $13.2M; ex-rebate up 10% YoY on price increases and improved gross-to-nets.
Net income $2.0M ($0.21 basic EPS) vs $1.5M ($0.24) prior year; includes $3.8M derivative warrant gain.
Adjusted EBITDA $(0.6)M includes EXXUA launch investments; cash $32.6M at Sep 30.
EXXUA (gepirone) on track for commercial launch in Q4 2025; patent extended to Sep 2030; targeting $22B MDD market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.